Clinical

Hepatitis B and C prevention programs improve detection, treatment, and liver outcomes, but screening, care access, and implementation gaps remain.

AI phenotyping identified cardiovascular and kidney disease as key predictors of rapid fibrosis progression, complications, and higher costs in MASH.

A common, underdiagnosed genetic disorder, hereditary hemochromatosis is costly when caught late and simple to treat when caught early.

INCA033989 showed responses across type 1 and type 2 mutant calreticulin-positive myelofibrosis, with phase 3 studies underway.

Gunn described her reaction to the SYNCHRONIZE-1 liver fat reduction data as genuinely compelling from a hepatology perspective, noting a reduction of up to 63% represents a level of hepatic fat clearance that could meaningfully transform the disease trajectory for patients, with the data also demonstrating reductions in non-invasive markers of fibrosis such as ELF and Pro-C3, adding further weight to the possibility that this combination could address not just fat accumulation but the fibrotic progression that drives the most serious liver-related morbidity.

This segment explores increasing interest from both patients and clinicians in ctDNA testing and emerging targeted therapies in hormone receptor–positive, HER2-negative metastatic breast cancer.

Gunn explained the scientific rationale for combining GLP-1 and glucagon receptor agonism in the context of MASH, noting that the liver contains glucagon receptors, making the combination a compelling strategy for achieving more direct hepatic targeting than GLP-1 receptor agonism alone can provide.

This segment explores patient perspectives and acceptance of biomarker-driven treatment strategies in hormone receptor–positive, HER2-negative metastatic breast cancer.

In this episode, 'Closing the Recognition Gap: Underdiagnosis, Patient Education, and Treatment Goals in Alzheimer's Disease Agitation,' the expert neurologists explored the following questions: Do you believe that Alzheimer's disease agitation is currently underdiagnosed? How are you educating patients and families? What are the treatment goals for patients with Alzheimer's disease agitation?

In 'The Burden of Alzheimer's Disease Agitation: Impact on Patients, Caregivers, and Quality of Life,' the expert neurologists examined the following critical questions: What is the impact that Alzheimer's disease agitation has on patients, as well as their caregivers, and what is the necessary education? How can it impact quality of life and impact families?

Voice changes may help detect asthma and COPD exacerbations early, supporting future remote disease monitoring.

In trials, the first oral PCSK9 inhibitor cut LDL cholesterol by up to 60%, which matched the efficacy of injectable PCSK9 therapies.

Christina Poh examined the highly individualized nature of the rituximab versus obinutuzumab decision in follicular lymphoma, framing it as a patient-specific assessment that must weigh efficacy advantages against a meaningfully higher tolerability burden that may not be appropriate for all patients.

Christina Poh reviewed the inMIND safety data, noting that the addition of tafasitamab to the lenalidomide and rituximab backbone produced a manageable safety profile that was generally consistent with the R² backbone alone with no major unexpected safety signals observed and overall good patient tolerability throughout the trial.

Respiratory rehabilitation improved exercise capacity in patients with COPD with and without suspected pulmonary hypertension.

New study validates CVI Range-CR for measuring real-world vision in kids with cerebral visual impairment and tracking change over time.

Female newborns were more likely than males to miss vitamin K prophylaxis and hepatitis B birth doses, highlighting sex-based gaps in preventive care.

The FDA approved LEQEMBI IQLIK for once-weekly at-home subcutaneous initiation in early Alzheimer's disease based on IV and extension study data.

Veligrotug is a newly FDA-approved treatment that can target the proptosis associated with thyroid eye disease.

The 2026 State of Dry Eye survey links DED treatment to improved emotional well-being and quality of life amid delays in care and awareness gaps.

JAK inhibitors are reshaping alopecia areata care, while global registries aim to address long-term safety and effectiveness data gaps.

Alexander Spira, MD, PhD, FACP, FASCO, explains why sarcoma treatment lags behind other solid tumors and the access, subtype, and biomarker barriers.

New review finds psoriasis biologics generally preserve kidney function, with IL-17 inhibitors showing potential renal benefits.

Ajay K. Nooka, MD, MPH, explains why CD38 exposure complicates trial applicability, how MRD could speed approvals, and what a dex-free future looks like.

Paul Hahn, MD, on what separates practice-changing retina therapies from niche ones, plus gene therapy and home-monitoring hurdles.